Biocon will acquire all of Viatris’ convertible preferred equity in Biocon Biologics for $400 million in cash and $415 million in newly issued Biocon shares
The project focuses on recovering high-quality polycarbonate, a valuable polymer material used in the construction of the filters
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
It's an acquisition that aims at forming one of the US's largest oncology trial networks
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
VitiPure serves as essential solubilizers, emulsifiers, and bioavailability enhancers in drug formulations
Ipca Laboratories receives three observations from USFDA for API facility at Tarapur
Valorum will advance the commercialization and distribution of Armlupeg in the United States
The center will offer training to super-specialist doctors and healthcare professionals in various fields
Granules Consumer Health serves as Granules’ front-end division for OTC products in the US
Sun Pharma to set up Rs. 3,000 crore greenfield formulations facility in MP
The BlueSeal Horizon 3.0T platform incorporates advanced magnet technology
The PCR-based test, delivered via Roche’s cobas liat system, allows results to be obtained during a patient consultation in GP practices and Emergency Rooms
LYMPHIR addresses a clear clinical need in a disease with limited treatment options
The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025
FDA's withholding of the PRV was contrary to law because no drug product containing phenobarbital sodium was 'previously approved'
Now a test that offers new precision in prostate cancer detection
Suven Life Sciences achieved 100% patient enrolment in Phase-2b clinical trial of Ropanicant for MDO
Subscribe To Our Newsletter & Stay Updated
